David M. Stout
Director
David Stout has served as a director of Jabil since September 2009. Mr. Stout was President, Pharmaceuticals, GlaxoSmithKline (GSK), with responsibility for global pharmaceutical operations, from 2003 to 2008. Prior to that, he served as President, U.S. Pharmaceuticals at GSK from 1999 to 2003, and as Senior Vice President, Sales and Marketing U.S., for SmithKline Beecham (SB) from 1996 until 1999. Prior to his time at SB and GSK, Mr. Stout held positions of increasing responsibility at Schering-Plough Corporation, from 1979 until 1996, including President of Schering Laboratories. He also serves on the board of directors of BlueWillow Biologics, a privately held company, and he previously served on the boards of Pharnext SA from 2018 to 2020, and Idorsia, LTD from 2017 to 2019, both biopharmaceutical companies, as well as Airgas Incorporated, Shire Pharmaceuticals and Actelion Pharmaceuticals, Ltd. Mr. Stout holds a B.S. in Biology from Western Maryland College (now McDaniel College).